GlassScriptPhysician profile
Adrienne S Berard
NPI 1972594166
$5,077.33
in general payments reported to CMS, 2019-2025
34 companies · $706 in 2025
The $706 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $846 · 2020: $622 · 2021: $1,038 · 2022: $592 · 2023: $490 · 2024: $783 · 2025: $706.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,980.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,979.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $853.64 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $843.10 | 2019-2025 | Linzess, Vraylar, Ubrelvy |
| Astellas Pharma US INC | $477.61 | 2019-2025 | Veozah |
| Pfizer INC. | $402.01 | 2019-2025 | |
| Esperion Therapeutics, INC. | $364.38 | 2020-2024 | Nexletol |
| Lilly USA, LLC | $363.11 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Novartis Pharmaceuticals Corporation | $235.43 | 2019-2025 | |
| Amgen INC. | $207.21 | 2019-2024 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $147.03 | 2019-2025 | Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $118.39 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Biohaven Pharmaceuticals, INC. | $117.40 | 2021 | |
| Janssen Pharmaceuticals, INC | $115.86 | 2019-2023 | Xarelto |
| Medtronic, INC. | $110.43 | 2021-2024 | Venaseal |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $87.60 | 2024-2025 | Caplyta |
| Amarin Pharma, INC. | $74.95 | 2019-2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $70.44 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $62.05 | 2021-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $53.75 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.68 | 2022-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.79 | 2019-2020 | |
| Antares Pharma, INC. | $33.62 | 2021-2022 | |
| Dexcom, INC. | $32.00 | 2023-2024 | Dexcom G6 Transmitter |
| Daiichi Sankyo INC. | $31.67 | 2021-2022 | |
| Impel Pharmaceuticals INC. | $24.31 | 2022 | |
| Sunovion Pharmaceuticals INC. | $23.54 | 2021 | |
| Sanofi-Aventis U.S. LLC | $17.25 | 2024 | |
| Eisai INC. | $16.65 | 2021 | |
| Clarus Therapeutics INC. | $16.51 | 2021 | |
| Upsher-Smith Laboratories LLC | $16.00 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.21 | 2022 | |
| Ibsa Pharma INC. | $13.67 | 2024 | Tirosint, Licart |
| Kowa Pharmaceuticals America, INC. | $12.94 | 2022 | |
| Roche Diabetes Care, INC. | $12.59 | 2019 | |
| Biogen, INC. | $12.51 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adrienne Berard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.